<- Go Home
LB Pharmaceuticals Inc
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Market Cap
$926.5M
Volume
266.5K
Cash and Equivalents
$320.7M
EBITDA
-$44.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$33.47
52 Week Low
$13.36
Dividend
N/A
Price / Book Value
2.45
Price / Earnings
-12.46
Price / Tangible Book Value
2.45
Enterprise Value
$564.4M
Enterprise Value / EBITDA
-12.77
Operating Income
-$45.1M
Return on Equity
19.55%
Return on Assets
N/A
Cash and Short Term Investments
$365.6M
Debt
$3.5M
Equity
$378.7M
Revenue
N/A
Unlevered FCF
N/A
Sector
Pharmaceuticals
Category
N/A